Volume 95 Issue 3
Issue Date: January 16, 2017
p. 10 ConcentratesIssue Date: January 16, 2017
Allergan targets nerves and the gut
Department: Business
Keywords: pharmaceuticals, lysosomal storage disease, Parkinson’s disease, microbiome
Keywords: pharmaceuticals, lysosomal storage disease, Parkinson’s disease, microbiome
Allergan has purchased an option to acquire Lysosomal Therapeutics (LTI), a biotech firm focused on neurodegeneration. Allergan would strike the deal following completion of a Phase 1b trial of LTI’s lead compound, LTI-291, a small-molecule targeting lysosomal storage diseases, including Parkinson’s. Allergan separately signed an agreement granting it worldwide rights to Assembly Biosciences’ microbiome gastrointestinal program, including preclinical compounds targeting ulcerative colitis and Crohn’s disease. Allergan will pay Assembly $50 million upfront.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society
Leave A Comment